This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pavie, J.
Right arrow Articles by Fantin, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pavie, J.
Right arrow Articles by Fantin, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2003, p. 2018-2021, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.2018-2021.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Influence of Reduced Susceptibility to Glycopeptides on Activities of Vancomycin and Teicoplanin against Staphylococcus aureus in Experimental Endocarditis

Juliette Pavie,1 Agnès Lefort,1 Marie-Cécile Ploy,2 Laurent Massias,3 Françoise Chau,1 Louis Garry,1 François Denis,2 and Bruno Fantin1*

INSERM EMI.U.9933, Faculté de Médecine Xavier Bichat,1 Service de Pharmacie, Hôpital Xavier Bichat, 75018 Paris,3 Laboratoire de Microbiologie, CHU de Limoges, 87042 Limoges Cedex, France2

Received 3 December 2002/ Returned for modification 4 February 2003/ Accepted 14 March 2003

The influence of reduced susceptibilities to glycopeptides on the activities of vancomycin and teicoplanin against an isogenic pair of clinical Staphylococcus aureus strains in experimental endocarditis was investigated. While vancomycin was similarly active against both strains, teicoplanin was approximately 100-fold less active against the resistant strain and selected for the emergence of more resistant subpopulations.

* Corresponding author. Mailing address: Service de Médecine Interne, Hôpital Beaujon, 100, Boulevard du Général Leclerc, 92118 Clichy Cedex, France. Phone: 33 1 40 87 58 90. Fax: 33 1 40 87 10 81. E-mail: bruno.fantin{at}bjn.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, June 2003, p. 2018-2021, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.2018-2021.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Andes, D., Craig, W. A. (2007). In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin. Antimicrob. Agents Chemother. 51: 1633-1642 [Abstract] [Full Text]  
  • Asseray, N., Jacqueline, C., Le Mabecque, V., Batard, E., Bugnon, D., Potel, G., Caillon, J. (2005). Activity of Glycopeptides against Staphylococcus aureus Infection in a Rabbit Endocarditis Model: MICs Do Not Predict In Vivo Efficacy. Antimicrob. Agents Chemother. 49: 857-859 [Abstract] [Full Text]  
  • Lefort, A., Pavie, J., Garry, L., Chau, F., Fantin, B. (2004). Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin. Antimicrob. Agents Chemother. 48: 1061-1064 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»